HEART FAILURE Study day November 2018 Sarah Briggs
Overview and Introduction • This course is an introduction and overview of heart failure. Normal heart function and basic pathophysiology of heart failure is explained. This will be then related to the diagnosis of heart failure and to the overall management of patients with heart failure. Device therapy will be explained, and also finally we will have discussion session about palliative care and heart failure.
Demographics of heart failure • Heart failure is serious • Heart failure is terminal • Heart failure is unpredictable • Heart failure causes severe symptoms • Heart failure outcomes are directly linked to good management and self monitoring. You can make a profound difference to a patient’s life
Plan of the Day • The normal heart • Pathophysiology of heart failure • Clinical presentation: History, assessment and clinical examination • Differential diagnosis, Investigations and Diagnosis • Pharmacological Management • Non medical Management • Palliative care • Device therapy
1. The Normal Heart
1. Normal Heart Function • The Cardiac Circulation • The Cardiac Valves • The Coronary Circulation • The Cardiac Electrical System
The Heart = A house!
2. Pathophysiology of Heart Failure
2. Pathophysiology of heart failure The two types of heart failure affecting the left ventricle. • HFrEF – can’t pump • HFPEF – can’t relax
2. Pathophysiology of heart failure Causes : Myocardial Infarction
2. Pathophysiology of heart failure Causes : Hypertension and aortic stenosis
Left Ventricular Hypertrophy
Other causes include: • Mitral regurgitation • Atrial fibrillation • Cardiomyopathies • Chemotherapy …….
Neurohormonal Activation • Increased Sympathetic activation • Reduction in renal perfusion results in activation of the RAAs • Brain natriuretic peptide release
The Natriuretic Peptide System
Heart failure is unpredictable!
3. History, Assessment and Clinical Examination
History • Presenting Complaint: • History of Presenting Complaint: • Past Medical History:
Its Systemic • Fatigue • Cool extremities • Pallor • Heavy leaden legs • Renal dysfunction • Anaemia • Acute/increasing breathlessness • Presents/punctuated with unpredictable episodes of fluid retention…..
3. Clinical Presentation Signs of Heart Failure - General Appearance – distress, gait, mobility, colour, pallor, tachypnoea, breathlessness, audible breath sounds,habitus, • Tachycardia/irregular • Hypertension/hypotension • Pallor/mallor flush • Elevated JVP (>5cm) • Heart Sounds – third heart sound • Added Breath Sounds – Crepitations/wheeze • Abdominal distension • Oedema – legs/sacral
The Burden of Heart Failure
Lets Talk about it!!.......
5. Differential Diagnoses
??? Is it ? Or is it? • Chest • Heart Failure? infection/pneumonia? • Pulmonary Embolism? • COPD? • N/AFLD? • Obesity? • Reduced Venous Return? • Lymphoedema?
Investigations • U&Es, LFT, FBC, Iron Profile, TSH, hba1C • BNP • ECHO • ECG • CXR • Holter monitor • 24hour BP • Also Cardiac MR, MPS, Angiography
Heart Failure?? Lets review the ECHO………
ECHO 1. Summary • Mild to moderate left ventricular hypertrophy with echogenic walls. The left ventricle is normal in size with severely reduced systolic function. LVEF - 31% (Teicholz). • The right ventricle is dilated, mildly hypertrophied with moderate to severely reduced systolic function. • Mild to moderate mitral regurgitation into a severely dilated left atrium. • Moderate tricuspid regurgitation into a severely dilated right atrium. • Mild pulmonary regurgitation. Trivial aortic regurgitation. • Right ventricular systolic pressure is 56-61 mmHg assuming a RAP of 10-15 mmHg. • Echo findings suggestive of pulmonary hypertension
ECHO 2 Summary • Overall left ventricular systolic function is severely reduced. LV ejection fraction is visually estimated at 30%. Right ventricle global systolic function is moderately reduced . • Aortic valve appears tricuspid, mildly thickened with reduced cusp excursion/mobility. ? mild aortic sclerosis. • Moderate mitral regurgitation. Moderate tricuspid regurgitation.. Mild pulmonary regurgitation. • RV / RA gradient 39 mmHg. Estimated PA systolic pressure is > 59 mmHg, (assuming RAp >20 mmHg). Pulmonary hypertension • indicated. • Large pleural effusion noted.
ECHO 3 • Left Ventricle Normal LV cavity size is seen with moderate systolic impairment. EF is estimated using biplane Simpson's method at 41%. • Global longitudinal strain is severely impaired at 10.6%. • There is evidence of global hypokinesis with more marked impairment inferior/ inferolaterally/ apical laterally ?significance. • Mild concentric LVH is seen with reversed E:A ratio of diastolic filling.
ECHO 4 • Summary • Moderate LV dilatation with moderate towards severe impairment - EF 36%. GLS- 10.5%. • Mild MR. • Gross LA dilatation. • Mild RV enlargement with mild impairment
ECHO 5 Summary • Severe LV dilatation is seen with severe LV systolic impairment. • There is thinned akinesis affecting the inferior and mid inferolateral region. Marked hypokinesis is seen elsewhere. • EF is unable to accurately quantified due to poor image quality and AF. • Visually EF is 15-20%. • Mild LVH is seen in the non-thinned regions. • Thin MV leaflets- opens well. • There is annular stretch seen (5.0cm). • Reduced MV leaflet apposition is seen with moderate MR. • Moderate RV impairment.
8. Pharmacological Management
Neurohormonal deactivation 1. A drenaline • Beta Blockers Dose Side Effects Monitoring
Neurohormonal Deactivation 2. A ngiotensin II • ACE Inhibition Dose Side Effects Monitoring
ARNI – Angiotensin receptor/Neprilysn Inhibition
Neurohormonal Deactivation 3. A ldosterone • MRA Dose Side Effects Monitoring
Symptomatic management • Diuretics Loop/thiazide Dose Side Effects Monitoring
Other Pharmacological agents and contraindications • Digoxin • Oral Anticoagulations – NOACS • Ivabradine • Antianginals • Antihypertensives • Palliative Medications • Contraindications
Challenges in giving HF DMT • Hypotension • Dizziness • CKD • Hyperkalaemia • Non compliance • Incontinence • Immobility • Insufficient support • Insufficient education • Clinician anxieties/insufficient support/education
Do you have any questions about medication?
9. Non Pharmacological Management
Non Pharmacological Management • DAILY WEIGHT • Anxiety/stress management • Depression/low mood • Support Groups • Hospice • Education • Salt intake • Fluid intake • Dry mouth
Non Pharmacological Management • Exercise • General weight management • Smoking, alcohol • Fatigue management – goal setting • Sleep – nocturia – important meds at night (BP) • Caffeine intake • Vaccinations • Holidays
11. Palliative Care – Lets discuss the challenges of palliative care in heart failure
10. Device Therapy
CRT and ICD NYHA class QRS interval I II III IV <120 milliseconds ICD if there is a high risk of sudden ICD and CRT not cardiac death clinically indicated 120 – 149 milliseconds ICD ICD ICD CRT-P without LBBB 120 – 149 milliseconds ICD CRT-D CRT-P or CRT-P with LBBB CRT-D ≥150 milliseconds with CRT-D CRT-D CRT-P or CRT-P or without LBBB CRT-D LBBB, left bundle branch block; NYHA, New York Heart Association
• https://www.youtube.com/watch?v=7hEw4o06Fwc • http://www.bostonscientific.com/en-US/patients/about- your-device/crt-devices/how-crts-work.html
Thank you so much!!
12/2/2014 NAMAS Cardiology Breakout Cathy Huyghe, CPC Objectives Discuss the importance of data quality in auditing Apply medical necessity guidelines to Evaluation and Management services Hear the 2015 Coding update for
706 views • 25 slides
ICD-10 Provider Education Antonietta Sculimbrene, MD MHA October 20 15 Avoid claims processing errors=denials or claim rejections for providers, by fostering an understanding of the process of and reasoning behind Palmettos development of
418 views • 26 slides
Disclosures: Rapid 12-Lead EKG Interpretation Goals for todays ECG Review: email@example.com Determine Right vs Left bundle branch block Diagnose Acute MI Diagnose old MI Location of the infarct
495 views • 24 slides
Machine Learning Methods for Mortality Prediction in Patients with ST Elevation Myocardial Infarction J. Vomlel 1 , H. Kru k 2 , P. T uma 2 , J. P cek 3 , and M. Hutyra 3 z re 1 Institute of Information Theory and Automation (
1.1k views • 60 slides
Supraventricular tachycardia from a left bundle branch block-An unusual presentation of Wolff- Parkinson-White syndrome Author(s): Abdul Rahim Wong, Nabil AbdurRazak, Saad Mohammad, Al-Hadlaq, Aida Hanum Ghulam Rasool, Abdullah Al-Jarallah Vol.
400 views • 5 slides
Dr. Sudarshan subedi et al., IJSIT, 2018, 7(2), 205-210 CASE PRESENTATION OF ST SEGMENTS ELEVATION IN LEAD AVR: ELECTROCARDIOGRAPHIC AND ANGIOGRAPHIC FINDINGS Dr. Sudarshan subedi 1* and Prof. Dr. Yang Shaning 2 1 Department of Cardiology, The
237 views • 6 slides
Intracoronary Compared with Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention Cardiac Magnetic Resonance Substudy of the AIDA STEMI trial Holger Thiele, MD; Jochen Whrle, MD; Henning Suenkel, BSc;
453 views • 24 slides
Case Presentation Case Presentation 79 year old gentleman underwent CABG 10 years ago: SVG to the LAD, SVG to the obtuse Coronary Artery Disease Coronary Artery Disease marginal branch, and SVG to the ramus intermedius vessel John A Larry
397 views • 14 slides
We are a responsibly - driven company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases SEELOS THERAPEUTICS June 2019 FORWARD-LOOKING STATEMENTS
458 views • 27 slides
OPIOID OVERDOSE PREVENTION Guidance for Implementing Overdose Prevention in Schools Presented by Debra Carey, MS, PPCNP-BC, AE-C November 2016 Background Deaths from opioid overdoses have reached epidemic levels in our community over the
368 views • 19 slides
CRF01_AE: Do we need a customized CCR5 antagonist treatment recommendation? Nico Pfeifer Max Planck Insitute for Informatics HIV coreceptor usage HIV coreceptor usage HIV coreceptor usage HIV coreceptor usage CRF01_AE update Recent
367 views • 15 slides
Calculation of the Minimum Anticipated Biological Effect Level (MABEL) and 1 st dose in human Jennifer Sims, PhD AstraZeneca Member of ABPI / BIA Early Stage Clinical Trials Taskforce Slide 1 Acknowledgements Acknowledgements ABPI/ BIA
482 views • 25 slides
Downloaded from http://bmjopen.bmj.com/ on January 12, 2018 - Published by group.bmj.com Open Access Research Clinical value of chest pain presentation and prodromes on the assessment of cardiovascular disease: a cohort study John Robson, 1
252 views • 7 slides
Objectives Review the impact of stroke, recognize signs and symptoms ACUTE STROKE CARE FOR Define risk factors Learn Pathophysiology of stroke THE EMS PROVIDER Learn Pre-hospital recommendations for Dispatch and EMS and
621 views • 16 slides
6/2/18 Acute Coronary syndrome 7th Annual Pharmacotherapy Conference ACS Pathophysiology rupture or erosion of a vulnerable, lipid- laden, atherosclerotic coronary plaque, resulting in exposure of circulating blood to highly thrombogenic
407 views • 17 slides
ECG Workshop Nezar Amir Case one A 61-year-old man with a history of hypertension and congestive heart failure presents to the emergency department with shortness of breath after eating breakfast. All of the following statements about his ECG
905 views • 55 slides
Diabetes and the Cardiovascular Connection Phoebe A. Ashley, M.D., FACC Phoebe A. Ashley, MD, FACC Oregon Cardiology, P.C. Oregon Cardiology, PC Medical Director, OHVI Cardiovascular Wellness & Medical Director, OHVI Cardiovascular
1.83k views • 133 slides
IMET 2000 PAL International Medical Education Trust Palestine ACUTE CORONARY SYNDROMES ACS Raed Abu Sham a, MD Internist and cardiologist Cardiac pacing and Electrophysiologist Senior Medical Education Officer Raed Abu Sham
1.06k views • 88 slides
Optimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event The DES he DES LA LATE TE Trial rial Cheol Whan Lee, MD, Seung-Jung Park, MD, PhD, On Behalf of the DES LATE Investigators Division of
620 views • 32 slides
Results of the 2019 WCHRI Research Day Oral and Poster Presentations WCHRI is pleased to have hosted our 12 th annual research day November 6, 2019. WCHRI research day offers a highly-engaged learning and networking environment that showcases
414 views • 4 slides
The Modern American Hospital Balancing Performance and Compliance in the Current Climate of Reform ORANGE COUNTY BAR ASSOCIATION HEALTH CARE LAW SECTION MEETING MCLE CREDIT 1.00 Craig B. Garner is a State Bar of California approved MCLE
1.1k views • 83 slides
International regulatory convergence strategic reflections from the ESC Professor Alan G Fraser Co-Chairman, ESC Task Force on Medical Devices 20 th March 2013 IMDRF Stakeholder Forum Governance of medical devices REGULATORS PHYSICIANS
512 views • 29 slides
Six-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent (total stent length >45mm) implantation: the IVUS-XPL randomized clinical trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial
598 views • 10 slides
Generalizing inferences about failure-time outcomes from randomized individuals to a target population Sarah Robertson Brown University sarah firstname.lastname@example.org June 2, 2019 1 / 34 Acknowledgments PCORI awards ME-1306-03758 and
567 views • 34 slides